# US 2019/0314517 A1 · Stable anti-cd79b immunoconjugate formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314517 A1
- Document ID: US20190314517A1
- Status: Published application
- Kind: A1
- Application number: 16/383,478
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Ankit R. PATEL; Jun LIU
- Web page: https://patentgrep.com/patent/US20190314517A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61J 1/10: Bag-type containers
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61K 47/6873: {the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.

## Claims

### Claim 1

A pharmaceutical composition comprising an anti-CD79b immunoconjugate and a surfactant, wherein the surfactant is at a concentration of at least 0.06% w/v, and wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and
p is a value from about 1 to about 8.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anti-CD79b immunoconjugate is at a concentration of about 5 mg/ml to about 60 mg/ml, about 10 mg/ml to about 50 mg/ml, about 10 mg/ml to about 40 mg/ml, about 10 mg/ml to about 30 mg/ml, or about 10 mg/ml to about 20 mg/ml.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml.

### Claim 4 (depends on 2, 3)

The pharmaceutical composition of claim 2 or 3, wherein the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml.

### Claim 5 (depends on 1, 2, 3)

The pharmaceutical composition of any one of claims 1-3, wherein the composition comprises the anti-CD79b immunoconjugate at a concentration of 10 mg/ml and the surfactant at a concentration of 0.06% w/v.

### Claim 6 (depends on 1, 2, 3, 4)

The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises the anti-CD79b immunoconjugate at a concentration of 20 mg/ml and the surfactant at a concentration of 0.12% w/v.

### Claim 7 (depends on 1, 2, 3, 4)

The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises the anti-CD79b immunoconjugate at a concentration of 20 mg/ml and the surfactant at a concentration of at least 0.12% w/v.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The pharmaceutical composition of any one of claims 1-7, wherein the surfactant is selected from the group consisting of: polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188 (P188), N-octyl-β-D glucopyranoside (OG), and a combination thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The pharmaceutical composition of any one of claims 1-8, wherein the composition further comprises a buffering agent.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the buffering agent is a histidine buffer or a succinate buffer.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the buffering agent is a histidine buffer.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the buffering agent is a succinate buffer.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the succinate buffer is a sodium succinate buffer.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the sodium succinate buffer is at a concentration of about 10 mM to about 200 mM.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the sodium succinate buffer is at a concentration of 10 mM.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The pharmaceutical composition of any one of claims 1-15, wherein the composition has a pH of about 5.0 to about 6.0.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the composition has a pH of 5.3.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The pharmaceutical composition of any one of claims 1-17, wherein the composition further comprises a sugar.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the sugar is at a concentration of about 100 mM to about 260 mM.

### Claim 20 (depends on 18, 19)

The pharmaceutical composition of claims 18-19, wherein the sugar is selected from the group consisting of: sucrose, mannitol, sorbitol, glycerol, dextran 40, and trehalose.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the sugar is sucrose.

### Claim 22 (depends on 22)

The pharmaceutical composition of claim 22, wherein the sucrose is at a concentration of 120 mM.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The pharmaceutical composition of any one of claims 1-22, wherein the composition has been reconstituted from a lyophilized cake.

### Claim 24

A pharmaceutical composition produced by lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and
p is a value from about 1 to about 8.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The pharmaceutical composition of any one of claims 1-24, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The pharmaceutical composition of any one of claims 1-25, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9 and the light chain comprises the amino acid sequence of SEQ ID NO: 10.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The pharmaceutical composition of any one of claims 1-26, wherein p is a value between about 2 and about 5.

### Claim 28

A pharmaceutical composition produced by lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The pharmaceutical composition of any one of claims 1-28, wherein p is about 3.5.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29)

The pharmaceutical composition of any one of claims 24-29, wherein the composition has a stability of about 48 months at 5° C.±3° C. when protected from light.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the stability of the composition is measured by size-exclusion high performance liquid chromatography (SE-HPLC).

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the composition has a main peak (area %) of at least 95.0 as measured by SE-HPLC.

### Claim 33 (depends on 28, 29, 30, 31, 32)

The pharmaceutical composition of claim any one of claims 28-32, wherein the stability of the composition is measured by imaged capillary isoelectric focusing (icIEF).

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the composition has a main peak (area %) of at least 58.0, an acid region (area %) of at most 32.0, and a basic region (area %) of at most 12.0 as measured by icIEF.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The pharmaceutical composition of any one of claims 24-34, wherein the pharmaceutical composition is a lyophilized cake.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 1-35, wherein the pharmaceutical composition is reconstituted with sterile water for injection (SWFI) to produce a reconstituted composition.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 1-35, wherein the pharmaceutical composition is reconstituted in about 7.2 ml SWFI to produce a reconstituted composition.

### Claim 38 (depends on 36, 37)

The pharmaceutical composition of claim 36 or 37, wherein the reconstituted composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30° C.

### Claim 39 (depends on 36, 37, 38)

The pharmaceutical composition of any one of claims 36-38, wherein the reconstituted composition is stable for at least 24, 48, or 72 hours upon storage at about 2° C. to about 8° C.

### Claim 40 (depends on 36, 37, 38, 39)

The pharmaceutical composition of any one of claims 36-39, wherein the reconstituted composition can be further diluted into an isotonic buffer in an intravenous (IV) bag to produce a diluted composition.

### Claim 41 (depends on 40)

The pharmaceutical composition of claim 40, wherein the final volume of the diluted composition in the IV bag is about 100 ml.

### Claim 42 (depends on 40, 41)

The pharmaceutical composition of claim 40 or 41, wherein the concentration of the immunoconjugate in the diluted composition is between about 0.72 mg/ml and about 2.7 mg/ml.

### Claim 43

A pharmaceutical composition produced by a process comprising the steps of:
(a) lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5, to produce a lyophilized composition;
(b) reconstituting the lyophilized composition with about 7.2 ml sterile water for injection (SWFI) to produce a reconstituted composition; and
(c) diluting the reconstituted composition into an isotonic buffer in an intravenous (IV) bag to produce the pharmaceutical composition,
wherein the final volume of the pharmaceutical composition in the IV bag is about 100 ml, and
wherein the final concentration of the immunoconjugate in the pharmaceutical composition is about 0.72 mg/ml or about 2.7 mg/ml.

### Claim 44 (depends on 43)

The pharmaceutical composition of claim 43, wherein p is about 3.5.

### Claim 45 (depends on 38, 39, 40, 41, 42, 43, 44)

The pharmaceutical composition of any one of claims 38-44, wherein the isotonic buffer is an 0.9% sodium chloride solution, an 0.45% sodium chloride solution, or a 5% dextrose solution.

### Claim 46

A liquid composition comprising a) between about 0.72-2.7 mg/ml polatuzumab vedotin; b) between about 0.36-0 1.35 mM sodium succinate; c) between about 0.51-16.24 mM sucrose; d) between about 0.0432-0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5 and about 5.7.

### Claim 47

A liquid composition comprising a) about 0.72 mg/ml polatuzumab vedotin; b) about 0.36 mM sodium succinate; c) about 0.51 mM sucrose; d) about 0.0432 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5.1 and about 5.4.

### Claim 48

A liquid composition comprising a) about 2.7 mg/ml polatuzumab vedotin; b) about 0 1.35 mM sodium succinate; c) about 16.24 mM sucrose; d) about 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5.1 and about 5.4.

### Claim 49 (depends on 46, 47, 48)

The liquid composition of any one of claims 46-48, wherein the volume of the liquid composition is between about 50 ml and about 100 ml.

### Claim 50 (depends on 49)

The liquid composition of claim 49, wherein the volume of the liquid composition is 50 ml.

### Claim 51 (depends on 49)

The liquid composition of claim 49, wherein the volume of the liquid composition is 100 ml.

### Claim 52

A pharmaceutical composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the pharmaceutical composition, when reconstituted in water, forms a liquid pharmaceutical composition comprising the anti-CD79b immunoconjugate at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant at a concentration of at least 0.06% w/v, the succinate buffer at a concentration of about 10 mM to about 200 mM, and the sugar at a concentration of about 100 mM to about 260 mM, wherein the liquid pharmaceutical composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and
p is a value from about 1 to about 8.

### Claim 53 (depends on 52)

The pharmaceutical composition of claim 52, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 54 (depends on 52, 53)

The pharmaceutical composition of claim 52 or 53, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.

### Claim 55 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 52, 53, 54)

The pharmaceutical composition of any one of claims 24-34 or 52-54 wherein the pharmaceutical composition is produced by lyophilization, and wherein the lyophilized pharmaceutical composition is stable for at least 6, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months upon storage at about 2° C. to about 8° C.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the lyophilized pharmaceutical composition is a lyophilized cake.

### Claim 57 (depends on 52, 53, 54, 55, 56)

The pharmaceutical composition any one of claims 52-56 wherein the pharmaceutical composition, following reconstitution, is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30° C.

### Claim 58 (depends on 52, 53, 54, 55, 56, 57)

The pharmaceutical composition of any one of claims 52-57, wherein the pharmaceutical composition, following reconstitution, is stable for at least 24, 48, or 72 hours upon storage at about 2° C. to about 8° C.

### Claim 59 (depends on 52, 53, 54, 55, 56, 57, 58)

The pharmaceutical composition of any one of claims 52-58, wherein the pharmaceutical composition, following reconstitution, is diluted into an isotonic buffer in an IV bag, wherein the surfactant concentration upon dilution in the IV bag is at least 0.003% w/v.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the surfactant concentration upon dilution in the IV bag is at least 0.004% w/v.

### Claim 61 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60)

The pharmaceutical composition of any one of claims 52-60, wherein the surfactant is polysorbate 20.

### Claim 62 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The pharmaceutical composition of any one of claims 52-61, wherein the sugar is sucrose.

### Claim 63 (depends on 52, 53, 54, 55, 56, 57, 58, 61, 62)

The pharmaceutical composition of anyone of claims 52-58 and 61-62, wherein the sucrose is at a concentration of 120 mM.

### Claim 64 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The pharmaceutical composition of any one of claims 52-63, wherein the succinate buffer is a sodium succinate buffer.

### Claim 65 (depends on 64)

The pharmaceutical composition of claim 64, wherein, following reconstitution but before dilution, the sodium succinate buffer is at a concentration of 10 mM.

### Claim 66 (depends on 52, 53, 54, 55, 56, 57, 58, 61, 62, 63, 64, 65)

The pharmaceutical composition of any one of claims 52-58 and 61-65, wherein the composition has a stability of about 7 days at 5° C.±3° C.

### Claim 67 (depends on 66)

The pharmaceutical composition of claim 66, wherein the stability of the composition is measured by size-exclusion high performance liquid chromatography (SE-HPLC).

### Claim 68 (depends on 67)

The pharmaceutical composition of claim 67, wherein the composition has a main peak (area %) of at least 95.0 as measured by SE-HPLC.

### Claim 69 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The pharmaceutical composition of any one of claims 52-68, wherein the stability of the composition is measured by imaged capillary isoelectric focusing (icIEF).

### Claim 70 (depends on 69)

The pharmaceutical composition of claim 69, wherein the composition has a main peak (area %) of at least 58.0, an acid region (area %) of at most 32.0, and a basic region (area %) of at most 12.0 as measured by icIEF.

### Claim 71 (depends on 52, 53, 54, 55, 56, 57, 58, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A glass vial containing the pharmaceutical composition of any one of claims 52-58 and 61-70.

### Claim 72

A liquid composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant is at a concentration of at least 0.06% w/v, the succinate buffer is at a concentration of about 10 mM to about 200 mM, and the sugar is at a concentration of about 100 mM to about 260 mM, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and
p is a value from about 1 to about 8.

### Claim 73 (depends on 72)

The liquid composition of claim 72, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 74 (depends on 72, 73)

The liquid composition of claim 72 or 73, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.

### Claim 75 (depends on 72, 73, 74)

The liquid composition of claim any one of claims 72-74, wherein the surfactant is polysorbate 20.

### Claim 76 (depends on 72, 73, 74, 75)

The liquid composition of any one of claims 72-75, wherein the sugar is sucrose.

### Claim 77 (depends on 76)

The liquid composition of claim 76, wherein the sucrose is at a concentration of about 120 mM.

### Claim 78 (depends on 72, 73, 74, 75, 76, 77)

The liquid composition of any one of claims 72-77, wherein the succinate buffer is a sodium succinate buffer.

### Claim 79 (depends on 78)

The liquid composition of claim 78, wherein the sodium succinate buffer is at a concentration of 10 mM.

### Claim 80 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The liquid composition of any one of claims 72-79, wherein the composition is diluted in an isotonic buffer.

### Claim 81 (depends on 80)

The liquid composition of claim 80, wherein the isotonic buffer is an 0.9% sodium chloride solution, an 0.45% sodium chloride solution, or a 5% dextrose solution.

### Claim 82 (depends on 80, 81)

The liquid composition of claim 80 or 81, wherein the composition that is diluted in an isotonic buffer is in an IV bag.

### Claim 83 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The liquid composition of any one of claims 72-79, wherein the composition has a stability of about 72 hours at 5° C.±3° C.

### Claim 84 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The liquid composition of any one of claims 72-79, wherein the composition has a stability of about 24 hours at 25° C.

### Claim 85 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The liquid composition of any one of claims 72-79, wherein the liquid composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30° C.

### Claim 86 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The liquid composition of any one of claims 72-79, wherein the liquid composition is stable for at least 24, 48, or 72 hours upon storage at about 2° C. to about 8° C.

### Claim 87

A lyophilized pharmaceutical composition comprising about 150 mg of an anti-CD79b immunoconjugate, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and
p is a value from about 2 to about 5.

### Claim 88

A lyophilized pharmaceutical composition comprising about 150 mg of polatuzumab vedotin, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose.

### Claim 89

A lyophilized pharmaceutical composition comprising about 140 mg of an anti-CD79b immunoconjugate, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and
p is a value from about 2 to about 5.

### Claim 90

A lyophilized pharmaceutical composition comprising about 140 mg of polatuzumab vedotin, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose.

### Claim 91

A lyophilized pharmaceutical composition comprising about 30 mg of an anti-CD79b immunoconjugate, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:
wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5.

### Claim 92

A lyophilized pharmaceutical composition comprising about 30 mg of polatuzumab vedotin, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose.

### Claim 93 (depends on 87, 89)

The lyophilized composition of any one of claims 87, 89, or 91, wherein p is about 3.5.

### Claim 94

A lyophilized pharmaceutical composition comprising about 140-150 mg of polatuzumab vedotin, about 8.4-9.0 mg polysorbate 20, about 8.27-8.88 mg succinic acid, about 3.80-4.08 mg sodium hydroxide, and about 288-309 mg sucrose.

### Claim 95 (depends on 87, 88, 89, 90, 91, 92, 93, 94)

The lyophilized pharmaceutical composition of any one of claims 87-94 wherein the lyophilized pharmaceutical composition is stable for at least 6, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months upon storage at about 2° C. to about 8° C.

### Claim 96 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95)

The lyophilized pharmaceutical composition of any one of claims 87-95, wherein the lyophilized pharmaceutical composition is a lyophilized cake.

### Claim 97

A liquid pharmaceutical composition comprising a) 5-60 mg/ml polatuzumab vedotin; b) 10-200 mM sodium succinate; c) 100-260 mM sucrose; d) 0.06-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5 and 6.

### Claim 98 (depends on 97)

The liquid composition of claim 97, comprising a) 10-55 mg/ml polatuzumab vedotin; b) 10-100 mM sodium succinate; c) 150-260 mM sucrose; d) 0.08-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5.1 and 5.6.

### Claim 99 (depends on 97)

The liquid composition of claim 97, comprising a) 15-40 mg/ml polatuzumab vedotin; b) 10-50 mM sodium succinate; c) 200-260 mM sucrose; d) 0.1-0.12% w/v polysorbate 20, wherein the pH of the liquid composition is between 5.2 and 5.4.

### Claim 100

A liquid pharmaceutical composition comprising a) 20 mg/ml polatuzumab vedotin; b) 10 mM sodium succinate; c) 120 mM sucrose; d) 0.12% w/v polysorbate 20, wherein the pH of the liquid composition is about 5.3.

### Claim 101 (depends on 97, 98, 99, 100)

The liquid composition of any one of claims 97-100, wherein the liquid composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30° C.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The liquid composition of any one of claims 97-101, wherein the liquid composition is stable for at least 24, 48, or 72 hours upon storage at about 2° C. to about 8° C.

### Claim 103

A method of treating a proliferative disorder in a patient in need thereof comprising administering to the patient the pharmaceutical composition or the liquid composition of any one of the preceding claims.

### Claim 104 (depends on 103)

The method of claim 103, wherein the proliferative disorder is cancer.

### Claim 105 (depends on 104)

The method of claim 104, wherein the cancer is a B cell proliferative disorder.

### Claim 106 (depends on 105)

The method of claim 105, wherein the B cell proliferative disorder is selected from the group consisting of: lymphoma, myeloma, non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), aggressive NHL, indolent lymphoma, follicular lymphoma (FL), relapsed aggressive NHL, relapsed indolent NHL, relapsed NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

### Claim 107 (depends on 106)

The method of claim 106, wherein the B cell proliferative disorder is non-Hodgkin's lymphoma (NHL).

### Claim 108 (depends on 106)

The method of claim 106, wherein the B cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).

### Claim 109 (depends on 106)

The method of claim 106, wherein the B cell proliferative disorder is relapsed NHL or refractory NHL.

### Claim 110 (depends on 106)

The method of claim 106, wherein the B cell proliferative disorder is follicular lymphoma (FL).
